Compound Summary
metolazone
Compound Information
metolazone
Compound Name: | metolazone |
Compound CID: | 4170 |
Synonyms: | metolazone 17560-51-9 Zaroxolyn Diulo Mykrox More... |
Iupac Name: | 7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide |
InChI: | InChI=1S/C16H16ClN3O3S/c1-9-5-3-4-6-14(9)20-10(2)19-13-8-12(17)15(24(18,22)23)7-11(13)16(20)21/h3-8,10,19H,1-2H3,(H2,18,22,23) |
InChIKey: | AQCHWTWZEMGIFD-UHFFFAOYSA-N |
Canonical Smiles: | CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl |
Isomeric Smiles: | CC1NC2=CC(=C(C=C2C(=O)N1C3=CC=CC=C3C)S(=O)(=O)N)Cl |
Molecular Weight: | 365.8 |
Molecular Formula: | C16H16ClN3O3S |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
metolazone
Molecular Weight: | 365.8 |
Molecular Formula: | C16H16ClN3O3S |
Hydrogen Bond Donor Count: | 2 |
Hydrogen Bond Acceptor Count: | 5 |
Rotatable Bond Count: | 2 |
Heavy Atom Count: | 24 |
Complexity: | 594 |
Synonyms
metolazone
| metolazone | metolazone |
|---|---|
metolazone |
17560-51-9 |
Zaroxolyn |
Diulo |
Mykrox |
Microx |
Metalozone |
Metenix |
Oldren |
7-Chloro-2-methyl-4-oxo-3-(o-tolyl)-1,2,3,4-tetrahydroquinazoline-6-sulfonamide |
Metolazona |
Metolazonum |
Metolazonum INN-Latin |
Metolazona INN-Spanish |
SR-720-22 |
7-Chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulfonamide |
SR 720-22 |
Metolazone (Zaroxolyn) |
6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- |
2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone |
7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamide |
7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2-dihydroquinazoline-6-sulfonamide |
UNII-NM7V2Y3G0U |
NM7V2Y3G0U |
7-chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide |
UNII-NN9U607695 |
CHEBI:64354 |
6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl- |
MFCD00069304 |
NN9U607695 |
NCGC00093985-07 |
Metalazone |
Xuret |
6-Quinazolinesulfonamide, 1,2,3,4-tetrahydro-7-chloro-2-methyl-4-oxo-3-o-tolyl- |
DSSTox_CID_25167 |
DSSTox_RID_80717 |
DSSTox_GSID_45167 |
Zaroxolyn (TN) |
SMR001230730 |
HSDB 3367 |
SR-05000001765 |
EINECS 241-539-3 |
BRN 0965506 |
Metolazone (JAN/USP/INN) |
Prestwick_333 |
CAS-17560-51-9 |
Metolazone, (+)- |
Metolazone, (-)- |
Metolazone USAN:USP:INN:BAN:JAN |
Spectrum_000456 |
Prestwick0_000112 |
Prestwick1_000112 |
Prestwick2_000112 |
Prestwick3_000112 |
Spectrum2_001741 |
Spectrum4_000229 |
Spectrum5_001237 |
CHEMBL878 |
(non-labelled)Metolazone-d7 |
SCHEMBL40558 |
BSPBio_000124 |
BSPBio_002422 |
KBioGR_000897 |
KBioSS_000936 |
5-25-09-00212 (Beilstein Handbook Reference) |
MLS002153316 |
MLS002154200 |
DivK1c_000275 |
SPECTRUM2300325 |
SPBio_001842 |
SPBio_002063 |
BPBio1_000138 |
GTPL4838 |
DTXSID6045167 |
BDBM25899 |
HMS500N17 |
KBio1_000275 |
KBio2_000936 |
KBio2_003504 |
KBio2_006072 |
NINDS_000275 |
BCPP000166 |
HMS1568G06 |
HMS1922L16 |
HMS2093P14 |
HMS2095G06 |
HMS2230J15 |
HMS3261J22 |
HMS3373C11 |
HMS3655M09 |
HMS3712G06 |
HMS3744I19 |
Pharmakon1600-02300325 |
BCP21574 |
EBD54305 |
HY-B0209 |
Tox21_110186 |
Tox21_113526 |
Tox21_500610 |
2-BROMO-5-NITRONICOTINICACID |
CCG-39450 |
NSC759581 |
s1610 |
AKOS015897109 |
Metolazone, >=98% (HPLC), solid |
Tox21_110186_1 |
BCP9000920 |
DB00524 |
KS-5139 |
LP00610 |
NSC 759581 |
NSC-759581 |
SDCCGSBI-0051460.P003 |
IDI1_000275 |
NCGC00093985-01 |
NCGC00093985-02 |
NCGC00093985-03 |
NCGC00093985-04 |
NCGC00093985-05 |
NCGC00093985-06 |
NCGC00093985-08 |
NCGC00093985-10 |
NCGC00093985-11 |
NCGC00093985-20 |
NCGC00261295-01 |
AS-13016 |
H024 |
SBI-0051460.P002 |
AB0012835 |
DB-044227 |
AB00052055 |
SW196612-3 |
D00431 |
7-chloro-2-methyl-4-oxo-3-o-tolyl-1,2,3,4 |
AB00052055-08 |
AB00052055_09 |
AB00052055_10 |
560M519 |
Q-201399 |
Q1169561 |
SR-05000001765-1 |
SR-05000001765-4 |
SR-05000001765-7 |
BRD-A61793559-001-05-7 |
BRD-A61793559-001-08-1 |
Metolazone, European Pharmacopoeia (EP) Reference Standard |
Metolazone, United States Pharmacopeia (USP) Reference Standard |
7-Chloro-2-methyl-3-(2-methylphenyl)-4-oxo-1,2,3,4-tetrahydro-6-quinazolinesulfonamide # |
Metolazone for system suitability, European Pharmacopoeia (EP) Reference Standard |
56436-31-8 |
56436-32-9 |
6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-, (+)- |
6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-, (-)- |
Experimental Data
metolazone
| Species | Dose | Unit | Control(Avg days) | Treatment(Avg days) | Avg/Med Lifespan Change(%) | Control(Max days) | Treatment(Max days) | Max Lifespan Change(%) | Significant | Strain | Gender | PubMed | Avg/Med Lifespan Change tab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Caenorhabditis elegans | 33.000000000000000 | umol/L | 6.000000000000000 | NS | N2 | 24134630 | Inactive | ||||||
| Caenorhabditis elegans | 10.000000000000000 | umol/L | 6.000000000000000 | 10.000000000000000 | 0.670000000000000 | S | N2 | 33216250 | Active |
Experimental Data Visualization
metolazone
Statistics Data
metolazone
| Species | Avg/Med Lifespan Change(%) | Max Lifespan Change(%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Caenorhabditis elegans | 6.000000000000000 | 2 | 2 |
Statistics Data Visualization
metolazone
